Insulin co-formulations: Discontinuation
Some insulin products are being discontinued.
12 February 2026 | Update
Six new products have been added to the broader insulin co-formulation discontinuation.
Eli Lilly is stopping supply of some insulin products in 2026. This only affects the vial presentation of the following products (the penfill versions remain available):
- Humalog
- Humulin NPH
- Humulin 30/70
- Humulin R
Novo Nordisk has added two products to the discontinuation list:
- Actrapid Penfill
- Protaphane Penfill
Educational resource for health care professionals
NZSSD has published an education resource giving an update on the availability and use of insulins in New Zealand.
Insulin therapy in diabetes: a clinical update [PDF] | NZSSD website(external link) (18 January 2026)
Affected products
The following products are being discontinued:
| Brand | Presentation | Chemical | Pharmacode | Supply ends | Funding ends |
|---|---|---|---|---|---|
| PenMix 30 | Inj human with neutral insulin 100 u per ml, 3 ml | Isophane insulin, insulin neutral | 785733 | October 2025 stock expires April 2026 |
1 May 2026 |
|
Humulin R |
Inj human 100 u per ml, 10 ml vial | Insulin neutral | 2703009 | end March 2026 | to be confirmed |
|
Apidra |
Inj 100 u per ml, 10 ml | Insulin glulisine | 2317109 | April 2026 | to be confirmed |
|
Humalog |
Inj 100 u per ml, 10 ml vial | Insulin lispro | 2702983 | end June 2026 | to be confirmed |
|
Humulin NPH |
Inj human 100 u per ml, 10 ml vial | Insulin isophane | 2702940 | end June 2026 | to be confirmed |
|
Humulin 30/70 |
Inj human with neutral insulin 100 u per ml, 10 ml vial | Insulin isophane with insulin neutral | 2702975 | end June 2026 | to be confirmed |
|
NovoMix 30 FlexPen |
Inj 100 iu per ml, 3 ml prefilled pen | Insulin aspart with insulin aspart protamine | 2404303 | December 2026 | to be confirmed |
|
Actrapid Penfill |
Inj human 100 u per ml, 3 ml | Insulin neutral | 797138 | End 2026 | to be confirmed |
|
Protaphane Penfill |
Inj human 100 u per ml, 3 ml | Insulin isophane | 797162 | End 2026 | to be confirmed |
People who use these products
There are funded alternatives. You can continue to access funded insulin treatment. You will need to talk to your prescriber as soon as possible to discuss the best options for your clinical situation.
For health care professionals
There are a number of other fully funded insulin products that may be suitable alternatives for your patients.
NZSSD has published an education resource giving an update on the availability and use of insulins in New Zealand.
Insulin therapy in diabetes: a clinical update [PDF] | NZSSD website(external link) (18 January 2026)
PenMix 30
Any remaining stock of this product expires in April 2026. It will be delisted from 1 May 2026.
Apidra
Only the 10 ml inj is being discontinued. Stock of the 3 ml injection and disposable pen will remain available. Fewer than 30 people are currently getting the 10 ml injection vial size.
Schedule listings for insulin glulisine(external link)
Humalog, Humulin NPH, Humulin 30/70, Humulin R vials
Only the 10 ml vial versions of these products are being discontinued. The 3 ml penfill presentations remain available.
NovoMix 30 FlexPen
The Novo Nordisk will stop supplying the NovoMix 30 FlexPen in December 2026. We funded Ryzodeg which may be a suitable alternative to NovoMix 30.
Ryzodeg (biphasic insulin degludec + insulin aspart) monograph | NZ Formulary(external link)
Actrapid Penfill and Protaphane Penfill
The 3 ml penfill presentations are being discontinued. The 10 ml vial presentations remain available.
More information
We encourage health care professionals to discuss a safe transition to an alternative funded product based on your patient’s individual needs.
Schedule listings for short-acting insulin preparations(external link)
Schedule listings for intermediate-acting insulin preparations(external link)
Insulin information in the NZ Formulary(external link)
Background
The insulin products on this page are supplied by a range of companies. These companies are discontinuing supply of some of their products that aren't used much or have been superseded by other insulin products.
All information about insulin discontinuations have been put on one page to allow health care providers to see the full range of affected products.
Who to contact
If you have questions about this issue, email enquiry@pharmac.govt.nz
Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.
Sign up to our email list for regular emails about supply issues and more(external link)
Pharmac is a government agency. We do not sell medicines or related products.